Compare VYX & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | ALVO |
|---|---|---|
| Founded | 1881 | 2013 |
| Country | United States | Luxembourg |
| Employees | 13500 | 1460 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | VYX | ALVO |
|---|---|---|
| Price | $7.72 | $3.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $13.67 | $8.00 |
| AVG Volume (30 Days) | ★ 2.2M | 638.7K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.02 | $2.94 |
| 52 Week High | $14.67 | $9.94 |
| Indicator | VYX | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 35.84 |
| Support Level | $7.67 | $2.99 |
| Resistance Level | $8.41 | $3.94 |
| Average True Range (ATR) | 0.41 | 0.17 |
| MACD | -0.10 | -0.03 |
| Stochastic Oscillator | 17.66 | 0.98 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.